Trial Profile

An early phase II study of RBM-007 in children with achondroplasia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 12 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umedaptanib pegol (Primary)
Indications Achondroplasia
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Sponsors Ribomic

Most Recent Events

05 Nov 2024 Results presented in a Ribomic Media Release.
03 Aug 2024 According to a Ribomic media release, first patient has been dosed in cohort 2 who have completed the observational study. A low-dose subcutaneous study cohort 1 has been completed enrolling six patients form observational study which enrolled 13 patients, which is expected to be completed by November of this year.
25 Apr 2022 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com